Kintor Pharmaceutical shares soared more than 11%
Kintor Pharmaceutical shares soared more than 11%
Shares of the Chinese drug developer-- $KINTOR PHARMA-B(09939.HK)$ increased 11.50% to 28.60 as at 10:50 am. $KINTOR PHARMA-B(09939.HK)$ surged over 170% in the last five trading days.
中国药品开发商的股票--$金达医药-B(09939.HK)$截至上午10：50，涨幅为11.50%至28.60$金达医药-B(09939.HK)$在过去的五个交易日中，涨幅超过170%。
Kintor Pharma's Proxalutamide demonstrated a reduction in hospitalization/mortality for patients with mild to moderate COVID-19 in Phase III MRCT study.
在第三阶段的MRCT研究中，Kintor Pharma公司的普罗沙鲁胺显示轻中度新冠肺炎患者的住院率/死亡率降低。
●Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p
●普罗沙鲁胺显著降低住院/死亡率，治疗超过7天的患者保护率达到100%(p
● Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors.
●普罗沙鲁胺降低了住院或死亡的风险，特别是在那些具有高危因素的患者。
● Proxalutamide demonstrates significant reduction in COVID-19 viral load and improved coronavirus-related symptoms.
●丙沙鲁胺显示出新冠肺炎病毒载量的显著降低和冠状病毒相关症状的改善。
● The Phase III multi-regional clinical trial (MRCT) enrolled 99% of patients in multiple centers accross the United States.
●第三阶段多区域临床试验在美国的多个中心招募了99%的患者。